This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Oncology Resources
Let's collaborate Boehringer Ingelheim

Oncology Resources

Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links to find further resources on key clinical data for afatinib and nintedanib, and the latest information on tumour types in which clinical investigations have been done or are ongoing.

Taking Cancer on Through Flavour

Details of the Boehringer Ingelheim ‘Taking Cancer on Through Flavour’ initiative.

Slide bank

An online tool for visitors to access educational slide resources and develop bespoke downloadable slide kits

Article library

A detailed bibliography of clinical data for afatinib* and nintedanib**, including trials, subgroup analyses, real-world data, case studies and review articles. The library is searchable by compound, tumour entity, phase and patient population

Download library

A library of downloadable resources containing up-to-date background information on key therapy areas in oncology, as well as on afatinib, nintedanib, and their pivotal clinical trials. Including slide decks, data visualisations and backgrounders

Related information

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

Nintedanib

Nintedanib (VARGATEF®) is approved in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy
Back to top

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.